NCT05445765 - Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Relapsed and/or Refractory Acute Myeloid LeukemiaHigh Risk Hematologic Malignancies

Interventions

BIOLOGICAL

anti-CD33 CAR T cells

Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.

Trial Locations (1)

Unknown

Hebei Yanda Lu Daopei Hospital, Langfang